Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | FDPS | P14324 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775181 | 0.94 | KMT2A (0.56) | KMT2AMAOBMEN1TSHRALDH1A1 | |
| SCHEMBL5050751 | 0.93 | KMT2A (0.55) | KMT2AMAOBMEN1TSHRALDH1A1 | |
| SCHEMBL6856717 | 0.90 | KMT2A (0.76) | KMT2AMAOBMEN1TSHRALDH1A1 | |
| SCHEMBL6939685 | 0.87 | TSHR (0.71) | TSHRPRSS1MAPK1 | |
| SCHEMBL10761788 | 0.87 | HPGD (0.64) | KMT2AMAOBMEN1TSHRPRSS1 | |
| SCHEMBL9249394 | 0.87 | KMT2A (0.63) | KMT2AMAOBMEN1TSHRALDH1A1 | |
| SCHEMBL16134424 | 0.87 | KMT2A (0.56) | KMT2AMAOBMEN1TSHRPRSS1 | |
| SCHEMBL18477634 | 0.86 | KMT2A (0.63) | KMT2AMAOBMEN1ALDH1A1 | |
| SCHEMBL470710 | 0.86 | KMT2A (0.66) | KMT2AMAOBMEN1TSHRALDH1A1 | |
| SCHEMBL7322978 | 0.86 | KMT2A (0.62) | KMT2AMAOBMEN1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018144900-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2018-08-09 | — | — | WO | disclosed |
| US-7087602-B2 | Cinnoline derivatives and use as medicine | ASTRAZENECA UK LIMITED (GB) | 2006-08-08 | — | — | US | disclosed |
| EP-0888310-B1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ASTRAZENECA AB (SE) | 2005-09-07 | — | — | EP | disclosed |
| US-20030199513-A1 | Cinnoline derivatives and use as medicine | ZENECA LIMITED | 2003-10-23 | — | — | US | disclosed |
| US-6514971-B1 | For use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans | ZENECA LIMITED (GB) | 2003-02-04 | — | — | US | disclosed |
| EP-0888310-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034876-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199513-A1 | Cinnoline derivatives and use as medicine | VEGFA, CNR1, CCR7 | KMT2A 4370/4885MAOB 3544/4885MEN1 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.